Japan Case: Cancer Drug Capivasertib Spikes Blood Sugar Fast

Japanese Case Report Highlights Hidden Blood Sugar Risk in Breast Cancer Treatment

A study from Japan, published in Surgical Case Reports (2025), documents a striking case of severe, rapid-onset high blood sugar triggered by capivasertib — a newer targeted therapy for advanced breast cancer. Researchers at Kagoshima City Hospital describe how a 69-year-old woman with no history of diabetes developed dangerously high blood sugar just two days after starting the drug.

What Is Capivasertib and Why Does It Matter?

Capivasertib (brand name Truqap) was approved by the FDA in 2023 for hormone receptor-positive, HER2-negative advanced breast cancer. It works by blocking a cellular signaling pathway called AKT — but that same pathway also plays a key role in how the body regulates insulin and blood sugar. Blocking it can essentially switch off the body's normal glucose control, sometimes dramatically.

What Happened in This Case?

The patient had completely normal blood sugar levels before starting treatment. Yet within 48 hours of her first dose of capivasertib combined with fulvestrant (a common hormone-blocking therapy), her blood glucose shot up to 522 mg/dL — a level classified as Grade 4 hyperglycemia, meaning life-threatening. For context, a normal fasting blood sugar in US terms is under 100 mg/dL, and anything above 300 mg/dL is considered a medical emergency by most US clinical standards.

The medical team acted quickly, starting continuous insulin through an IV to bring her levels down and prevent diabetic ketoacidosis (DKA), a potentially fatal complication. Her blood sugar normalized within half a day. She was discharged six days later and required no ongoing insulin or diabetes medication afterward.

What Makes This Japanese Perspective Unique?

Most US clinical data on capivasertib side effects come from large clinical trials that may not fully capture real-world, rapid-onset cases in older patients. This Japanese case report is valuable because it describes close inpatient monitoring as a key reason the patient avoided DKA — a level of glucose surveillance that is not always standard in US outpatient oncology settings. Japanese hospitals often have more structured inpatient observation protocols during early treatment cycles, which may give clinicians an early-warning advantage.

Does This Align With US Guidelines?

The FDA's prescribing information for capivasertib does include hyperglycemia as a known risk and recommends monitoring blood glucose before and during treatment. However, this case underscores that current guidance may underestimate how fast dangerous glucose elevations can occur — sometimes within just two days — leaving little margin for outpatient detection.

Why This Matters for US Patients

• If you or a loved one is starting capivasertib for breast cancer treatment, ask your oncologist about a blood sugar monitoring plan before your first dose.
• Even patients with no history of diabetes or prediabetes are at risk for severe hyperglycemia on this drug.
• Early detection is critical — the difference between a manageable glucose spike and a life-threatening DKA event may come down to how quickly blood sugar is checked and acted upon.
• People who already have diabetes or prediabetes may face even greater risk and should discuss this explicitly with their care team.

Staying on top of your baseline glucose health is more important than ever when navigating cancer treatment. Tools and education available at mdsdiabetes.com can help you and your caregivers understand blood sugar targets, recognize warning signs, and have more informed conversations with your medical team.

Citation

Nomoto, Mukai, Eguchi (2025). A Case of Grade 4 Hyperglycemia Induced by Capivasertib and Successfully Managed with Early Insulin Intervention. Surgical Case Reports. PMID: 41399756. DOI: 10.70352/scrj.cr.25-0514. Country of Origin: Japan — Department of Breast Surgery, Kagoshima City Hospital, Kagoshima, Japan.